KeyBank National Association
VKTX icon

KeyBank National Association’s Viking Therapeutics VKTX Stock Holding History

KeyBank National Association’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-28,000
Closed -$81K – 1088
2022
Q2 		$81K Hold
28,000
– – ﹤0.01% 1045
2022
Q1 		$84K Hold
28,000
– – ﹤0.01% 1052
2021
Q4 		$129K Buy
+28,000
New +$157K ﹤0.01% 1063

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KeyBank National Association's VKTX Position: Q3 2022 in Review

KeyBank National Association sold out of Viking Therapeutics (VKTX) in Q3 2022, closing a stake of 28,000 shares — an estimated $81K sold.

KeyBank National Association first reported a position in VKTX in Q4 2021 and held it in 3 quarters. The position peaked at $129K in Q4 2021. 107 funds tracked by Wall St. Rank hold VKTX as of Q3 2022.

  • KeyBank National Association reported no remaining Viking Therapeutics position as of Q3 2022 after selling out during the quarter.
  • KeyBank National Association sold 28,000 Viking Therapeutics shares in Q3 2022, an estimated $81K.
  • KeyBank National Association first reported a position in Viking Therapeutics in Q4 2021 and held it in 3 quarters.
  • KeyBank National Association's Viking Therapeutics position peaked at $129K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2022.

Based on KeyBank National Association's 13F filing for Q3 2022, filed 27 Oct 2022.